Is It Necessary to Use Three Mandatory Loading Doses When Commencing Therapy for Neovascular Age-Related Macular Degeneration Using Bevacizumab? (BeMOc Trial)

Eye - United Kingdom
doi 10.1038/eye.2013.93
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration

Archives of Ophthalmology
2007English

Contrast Sensitivity Outcomes in the ABC Trial: A Randomized Trial of Bevacizumab for Neovascular Age-Related Macular Degeneration

Investigative Ophthalmology and Visual Science
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2011English

Aflibercept for Neovascular Age-Related Macular Degeneration

Cochrane Database of Systematic Reviews
2016English

Single-Session Photodynamic Therapy Combined With Intravitreal Bevacizumab and Triamcinolone for Neovascular Age-Related Macular Degeneration

BMC Ophthalmology
MedicineOphthalmology
2007English

Macular Atrophy in Neovascular Age Related Macular Degeneration

Journal of Clinical Review & Case Reports
2019English

IL-18 Is Not Therapeutic for Neovascular Age-Related Macular Degeneration

Nature Medicine
BiochemistryMedicineGeneticsMolecular Biology
2014English

Neovascular Age-Related Macular Degeneration Is Associated With Cataract Surgery

Acta Ophthalmologica
MedicineOphthalmology
2017English

Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine
Medicine
2006English

One-Year Outcomes of 1 Dose Versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial

Journal of Ophthalmology
Ophthalmology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy